These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 37706187)

  • 1. Clostridioides
    Gawey BJ; Khanna S
    Gastroenterol Hepatol (N Y); 2023 Jun; 19(6):319-328. PubMed ID: 37706187
    [No Abstract]   [Full Text] [Related]  

  • 2. Microbiota restoration therapies for recurrent
    DuPont HL; DuPont AW; Tillotson GS
    Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the gut microbiome in colonization resistance and recurrent
    Seekatz AM; Safdar N; Khanna S
    Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
    Lavoie T; Appaneal HJ; LaPlante KL
    Clin Infect Dis; 2023 Dec; 77(Suppl 6):S447-S454. PubMed ID: 38051964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SER-109 (VOWST
    Blair HA
    Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota changes associated with
    Gonzales-Luna AJ; Carlson TJ; Garey KW
    Gut Microbes; 2023; 15(1):2223345. PubMed ID: 37318134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
    Khanna S
    J Intern Med; 2021 Aug; 290(2):294-309. PubMed ID: 33856727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent
    Wang Y; Hunt A; Danziger L; Drwiega EN
    Antibiotics (Basel); 2024 May; 13(5):. PubMed ID: 38786164
    [No Abstract]   [Full Text] [Related]  

  • 10. Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent
    Stallhofer J; Steube A; Katzer K; Stallmach A
    Visc Med; 2024 Apr; 40(2):82-91. PubMed ID: 38584858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutics for
    Khanna S; Voth E
    Expert Rev Gastroenterol Hepatol; 2023; 17(9):903-911. PubMed ID: 37606962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.
    Pipek B; Valentová H; Fojtík P; Urban O
    Cas Lek Cesk; 2022; 161(3-4):126-130. PubMed ID: 36100450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.
    Berry P; Khanna S
    BioDrugs; 2023 Nov; 37(6):757-773. PubMed ID: 37493938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbial ecology between
    Kamiya S
    Biosci Microbiota Food Health; 2023; 42(4):229-235. PubMed ID: 37791342
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-Term Bacterial and Fungal Dynamics following Oral Lyophilized Fecal Microbiota Transplantation in Clostridioides difficile Infection.
    Haifer C; Paramsothy S; Borody TJ; Clancy A; Leong RW; Kaakoush NO
    mSystems; 2021 Feb; 6(1):. PubMed ID: 33531405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal Microbiota Transplantation.
    Cheng YW; Fischer M
    Clin Colon Rectal Surg; 2023 Mar; 36(2):151-156. PubMed ID: 36844708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial.
    Kelly CR; Khoruts A; Staley C; Sadowsky MJ; Abd M; Alani M; Bakow B; Curran P; McKenney J; Tisch A; Reinert SE; Machan JT; Brandt LJ
    Ann Intern Med; 2016 Nov; 165(9):609-616. PubMed ID: 27547925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.
    Bernard R; Hourigan SK; Nicholson MR
    J Pediatric Infect Dis Soc; 2021 Nov; 10(Supplement_3):S58-S63. PubMed ID: 34791396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
    Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
    BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live Biotherapeutic Products for the Prevention of Recurrent
    Pettit NN; Shaeer KM; Chahine EB
    Ann Pharmacother; 2024 Mar; ():10600280241239685. PubMed ID: 38546138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.